STUDY WARNS OF SERIOUS ADVERSE EVENTS FOLLOWING COVID VACCINE INJECTION
Harold Saive
STUDY WARNS OF SERIOUS ADVERSE EVENTS FOLLOWING
COVID VACCINE INJECTION
A study published yesterday in the journal Vaccine titled
“Serious adverse events of special interest following mRNA
COVID-19 vaccination in randomized trials in adults.”
The researchers used Pfizer and Moderna’s own randomized,
placebo-controlled trials and compared them against an industry
list of common adverse events following vaccination. Guess what
they found?
Combined, there was a 16% higher risk of serious adverse events
in mRNA vaccine recipients … points to the need for formal
harm-benefit analyses … release of participant level datasets…
The Pfizer trial exhibited a 36% higher risk of serious adverse
events in the vaccine group[.]
That’s not good for business.
You can add this study to the ever-growing list of journal
articles critical of the jabs. Remember: jab-critical studies
have been embargoed until just recently; journal editors have
simply refused to print them because they “could cause vaccine
hesitancy.”
Something is changing.
Serious adverse events of special interest
following mRNA COVID-19 vaccination in randomized trials in
adults
https://www.sciencedirect.com/science/article/pii/S0264410X22010283
Abstract
Introduction
In 2020, prior to COVID-19 vaccine rollout, the Brighton
Collaboration created a priority list, endorsed by the World
Health Organization, of potential adverse events relevant to
COVID-19 vaccines. We adapted the Brighton Collaboration list to
evaluate serious adverse events of special interest observed in
mRNA COVID-19 vaccine trials.
Methods
Secondary analysis of serious adverse events reported in the
placebo-controlled, phase III randomized clinical trials of
Pfizer and Moderna mRNA COVID-19 vaccines in adults (NCT04368728
and NCT04470427), focusing analysis on Brighton Collaboration
adverse events of special interest.
Results
Pfizer and Moderna mRNA COVID-19 vaccines were associated with
an excess risk of serious adverse events of special interest of
10.1 and 15.1 per 10,000 vaccinated over placebo baselines of
17.6 and 42.2 (95 % CI −0.4 to 20.6 and −3.6 to 33.8),
respectively. Combined, the mRNA vaccines were associated with
an excess risk of serious adverse events of special interest of
12.5 per 10,000 vaccinated (95 % CI 2.1 to 22.9); risk ratio
1.43 (95 % CI 1.07 to 1.92). The Pfizer trial exhibited a 36 %
higher risk of serious adverse events in the vaccine group; risk
difference 18.0 per 10,000 vaccinated (95 % CI 1.2 to 34.9);
risk ratio 1.36 (95 % CI 1.02 to 1.83). The Moderna trial
exhibited a 6 % higher risk of serious adverse events in the
vaccine group: risk difference 7.1 per 10,000 (95 % CI –23.2 to
37.4); risk ratio 1.06 (95 % CI 0.84 to 1.33). Combined, there
was a 16 % higher risk of serious adverse events in mRNA vaccine
recipients: risk difference 13.2 (95 % CI −3.2 to 29.6); risk
ratio 1.16 (95 % CI 0.97 to 1.39).
See TOWN SQUARE NEWS Updates: https://groups.google.com/g/town-square-news
